Characterizing Acute Exercise Response in Restrictive Eating Disorders
Abstract
Individuals with eating disorders (ED) represent a high-priority clinical population, with among the highest mortality rates of any psychiatric disorder, and driven exercise (DEx) is a symptom evidenced in up to 80% of those with EDs that increases impairment and negatively impacts treatment outcome. This study will develop tasks to characterize cognitive, affective, and biological response to exercise among adolescent and young adult females with EDs and determine whether acute exercise response associates with free-living activity and DEx. This R21 project will provide foundational data to guide research and development of treatments that are more precisely targeted to the symptom of driven exercise and to ultimately improve clinical outcomes associated with EDs.
Conditions: Eating Disorders.
Primary outcome: Body Image State Scale (BISS) Score: Average of All BISS 6-items; Appearance-Item Score From Body Image State Scale (BISS); Average Person-Item Score From Body Image State Scale (BISS); Looks-Item Score From Body Image State Scale (BISS); Physical Attraction-Item Score From Body Image State Scale (BISS); Shape-Item Score From Body Image State Scale (BISS); Weight-Item Score From Body Image State Scale (BISS); Physical Activity Affect Scale (PAAS): Anxious-Item Score; Physical Activity Affect Scale (PAAS): Calm-Item Score; Physical Activity Affect Scale (PAAS): Crummy-Item Score; Physical Activity Affect Scale (PAAS): Enthusiastic-Item Score; Physical Activity Affect…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 74 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.